BLTE Chief Medical Officer Peter Sells $1.4M of Stock
Scholl Hendrik Peter sold 10,000 shares of BLTE, valued at $1.41 million, on June 16, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Scholl Hendrik Peter, Chief Medical Officer at Belite Bio, Inc ($BLTE), sold 10,000 shares at an average price of $140.57, worth about $1.41 million, on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $BLTE is up 5.0% after 1 week, up 9.0% after 1 month and up 3.3% to date (from the $138.19 close on Jun 16, 2026).
BLTE
Belite Bio, Inc
Key Points
- Scholl Hendrik Peter, BLTE's Chief Medical Officer, sold 10,000 shares worth $1.41 million on June 16, 2026.
- BLTE shares are currently trading at $138.19, with a robust presence from institutional investors.
- Analysts maintain a positive outlook on BLTE, with several firms reiterating buy ratings and price targets above $200.
Get $BLTE trade alerts by text
We text you when insiders, Congress or big funds trade $BLTE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Belite Bio, Inc alert may contain errors. Disclosures
On June 16, 2026, Scholl Hendrik Peter, the Chief Medical Officer of BLTE, sold 10,000 shares of the company. The shares were sold at an average price of $140.57, totaling around $1.41 million. This transaction was not part of a pre-planned trading program.
Other Institutional Activity in BLTE
Several institutional investors have been active in BLTE shares. Darwin Global Management, Ltd. increased its holdings by 29,708 shares, bringing its total to 3,057,412 shares valued at approximately $456.1 million. Paradigm Biocapital Advisors LP added 1,114,784 shares, ending with the same number of shares worth about $177.7 million. UBS Group AG significantly boosted its position by 639,607 shares, reaching a total of 768,359 shares valued at $122.5 million. Meanwhile, RTW Investments, LP maintained its stake with 715,332 shares worth $114.1 million.
Belite Bio, Inc Stock Down 19.2%
BLTE shares are currently trading at $138.19. The stock has seen active trading and significant institutional interest, contributing to its market dynamics. Analysts have shown optimism about BLTE's future, as reflected in their ratings and price targets.
Insider Buying and Selling at Belite Bio, Inc
In addition to Scholl Hendrik Peter's recent sale, Nathan Mata, the Chief Scientific Officer, has also been active. Mata sold shares on several occasions in May 2026 under a pre-planned trading program. His sales included 666 shares on May 7, and multiple transactions of 1,000 shares each from May 1 to May 6, with prices ranging from $153.21 to $155.78.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on BLTE. On May 26, 2026, Mizuho maintained its buy rating with a price target of $215. HC Wainwright & Co. reiterated its buy rating with a $200 target on May 21. Previously, on March 3, Morgan Stanley maintained a buy rating with a $201 target, while Cantor Fitzgerald set a target of $266.
About BLTE
BLTE is a company involved in the biotechnology sector, focusing on innovative medical solutions. The company is led by a team dedicated to advancing healthcare technologies. With a strong research and development pipeline, BLTE seeks to address unmet medical needs and improve patient outcomes.
Bottom Line
This insider transaction by Scholl Hendrik Peter is part of regular trading activity, reflecting individual investment decisions. Investors often monitor such insider activities to gauge management's sentiment about the company's prospects. The stock continues to attract institutional interest, and analysts are optimistic about its future potential, as evidenced by recent buy ratings and high price targets.
Related Filing Alerts
Source: Scholl Hendrik Peter's Form 4 filing on $BLTE (Jun 16, 2026). Find the original filing: BLTE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts